Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Update

Posted by Stanley Muller on Jun 15th, 2026

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA – Get Free Report) was the recipient of a large increase in short interest during the month of May. As of May 29th, there was short interest totaling 45,360 shares, an increase of 67.7% from the May 14th total of 27,047 shares. Approximately 1.0% of the shares of the company are sold short. Based on an average trading volume of 165,199 shares, the short-interest ratio is presently 0.3 days.

Sonoma Pharmaceuticals Price Performance

Shares of SNOA stock traded up $0.02 during mid-day trading on Monday, hitting $1.11. The stock had a trading volume of 18,579 shares, compared to its average volume of 117,515. Sonoma Pharmaceuticals has a fifty-two week low of $0.85 and a fifty-two week high of $6.92. The firm has a market cap of $5.32 million, a PE ratio of -0.54 and a beta of 1.29. The company’s 50-day simple moving average is $1.49 and its 200-day simple moving average is $2.53.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded Sonoma Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, April 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Sonoma Pharmaceuticals has an average rating of “Sell”.

Read Our Latest Stock Analysis on SNOA

Institutional Investors Weigh In On Sonoma Pharmaceuticals

A hedge fund recently bought a new stake in Sonoma Pharmaceuticals stock. McKinley Carter Wealth Services Inc. acquired a new stake in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 11,193 shares of the company’s stock, valued at approximately $41,000. McKinley Carter Wealth Services Inc. owned approximately 0.66% of Sonoma Pharmaceuticals at the end of the most recent quarter. 1.95% of the stock is owned by hedge funds and other institutional investors.

Sonoma Pharmaceuticals Company Profile

(Get Free Report)

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.